To identify mannosyl (Man)-containing intermediates of the human glycoinositol phospholipid (GPI) anchor pathway and examine their expression in paroxysmal nocturnal hemoglobinuria (PNH), mannolipid products deriving from in vitro guanosine diphosphate [3HJMan labeling of HeLa cell microsomes were characterized. The defined GPI species were correlated with products deriving from in vivo [3HJMan labeling of normal and (GPI-anchor defective) affected leukocytes. (designated H1-H8) showed that all but Hi (Dol-P-Man) were sensitive to HNO2 deamination and serum GPI-specific phospholipase D digestion but were resistant to phosphatidylinositol-specific phospholipase C digestion unless previously deacylated with mild alkali.
(designated H1-H8) showed that all but Hi (Dol-P-Man) were sensitive to HNO2 deamination and serum GPI-specific phospholipase D digestion but were resistant to phosphatidylinositol-specific phospholipase C digestion unless previously deacylated with mild alkali.
[3H]Man label in H3, H4, and H6 but not in H5 or H7 was efficiently released into the aqueous phase by jack bean a-mannosidase digestion. BioGel P-4 and AX-5 sizing of the dephosphorylated core glycan fragments ofH6 and H7 gave values that coincided precisely with the corresponding glycan fragments from the fully assembled Tryp anchor donor A' (P2). Affected leukocytes from four patients with PNH supported formation of GkcNAc-and GlcN-PI but all failed to express H6 and H7 as well as H8 and two showed complete absence of earlier Man-containing intermediates. These rindings argue that human intracellular GPI mannolipids are built on acylated inositol phospholipids, that H6 and H7 contain differentially phosphoethanolamine-substituted Man3-GIcNinositol cores, and that PNH cells are defective in conversion of GlcN-PI into these more mature mannolipid structures.
Cell-surface proteins that are membrane anchored by covalently attached glycoinositol phospholipid (GPI) structures are widely distributed on eukaryotic cells. Experimental evidence to date (reviewed in ref. 1) indicates that, despite individual variations, the GPI-anchoring units of these proteins share a common core structure ( Fig. 1) consisting of a phosphoethanolamine (P-Etn), three mannosyl (Man) residues, and a nonacetylated GlcN linked to an inositol phospholipid. This inositol phospholipid is characteristically phosphatidylinositol-specific phospholipase C (PI-PLC) sensitive but it may be PI-PLC resistant due to inositol acylation. In all cases studied, GPI-anchoring moieties appear to be preassembled in the endoplasmic reticulum (ER) and, once synthesized, transferred en bloc to primary translation products immediately upon their emergence from ribosomes. Although more than 50 proteins containing these structures have been identified, information concerning the biochemical pathway(s) responsible for their intracellular GPI-anchor assembly and protein incorporation is only beginning to emerge.
Among human GPI-anchored proteins are the decayaccelerating factor (DAF) and CD59, membrane-associated regulators of the complement cascade which protect host tissues from autologous complement attack (reviewed in refs. [2] [3] [4] . Deficient expression of these proteins underlies an acquired hemolytic disorder termed paroxysmal nocturnal hemoglobinuria (PNH), and the lesion responsible for the deficit has been traced to defective GPI-anchor pathway function in a bone marrow stem cell(s) (5) . The precise site(s) of interruption in the pathway, however, remains unidentified.
In a previous communication (6), we reported on the use of an in vitro experimental system employing hypotonic cell lysates to study mammalian GPI-anchor biosynthesis. The experimental system parallels that used for analyses of GPIanchor structures synthesized in Trypanosoma brucei (Tryps) (7, 8) . We previously demonstrated that mammalian cells transfer GlcNAc from UDP to a PI acceptor and rapidly deacetylate the GlcNAc-PI product to generate GlcN-PI, two species (designated GPI-A and -B) that correspond to the two initial intermediates in the Tryp GPI-anchor pathway (7, 8) . We were further able to show that cell lysates of GPI-anchordefective leukocytes from two PNH patients were able to support these biochemical conversions with normal efficiencies.
In the present communication, we report on the extension of this experimental system to characterize further steps in the human GPI-anchor pathway. We also report on the partial localization within these further steps of the block(s) in GPI-anchor synthesis that undermines expression of inhibitors were purchased from Sigma. Bacillus thuringiensis PI-PLC was provided by T. Rosenberry (Case Western Reserve University, Cleveland, OH). GPI-specific phospholipase D (GPI-PLD) was obtained from K.-S. Huang (Hoffmann-La Roche). Jack bean a-mannosidase was purchased from Oxford.
Murine anti-human DAF monoclonal antibody (mAb) IA10 (IgG2a) was prepared as described (9) and rat anti-human CD59 mAb YTH53.1 (IgG2a) was provided by P. Lachmann (Cambridge University, Cambridge, England). Appropriate murine and rat nonrelevant mAbs and fluorescein isothiocyanate-conjugated sheep anti-murine and goat anti-rat immunoglobulins were purchased from Organon Teknika-Cappel.
Cell Preparations. Tryps were expanded, human cells were cultured, and hypotonic lysates of each were prepared as described (6) . Subcellular fractionation of HeLa cells was conducted as described (10) . The rough microsome fraction was recovered at the 1.55/1.8 M sucrose interface. PNH cells stained with IA10 and YTH53.1 were analyzed on a Becton Dickinson FACStarPLUS flow cytometer. In patients (M.W. and S.T.) with DAF/CD59-positive polymorphonuclear leukocytes (PMNs), affected cell subsets were enriched by anti-DAF cell-affinity chromatography (5).
Biosynthetic Labeling. Human cell lysates were centrifuged and particulates were washed as described (6) . Tryp lysates and purified microsomes were used unwashed with the buffer adjusted to contain the same constituents. Cell preparations were added to 10 ,uCi of either GDP-[3H]Man or UDP-
[3H]GlcNAc in a final vol of 200 IlI containing 5 mM MnCI2, 1 mM ATP, 0.5 mM dithiothreitol, and tunicamycin (0.2 ,ug/ml). Intact cells (2 x 107) were preincubated for 60 min in 10 ml of glucose-free RPMI medium containing 10%o dialyzed fetal bovine serum, glucose (10 ,ug/ml), and tunicamycin (10 ,ug/ml) and then labeled for 45 min with 250 ,uCi of [3H]Man.
Reaction mixtures were extracted with chloroform (Chl)/ methanol, and dried extracts were partitioned in butanol/ water (6) .
Enzymatic and Chemical Treatments. Sphingomyelinase digestions were performed as described (11) using enzyme pretested for activity with sphingomyelin. HNO2 deaminations and GPI-PLD and PI-PLC digestions were performed as described (6) except that with PI-PLC buffer containing 2 mM deheptanoyl lecithin instead of 0.2% Triton X-100 was used. For a-mannosidase digestions, dried lipids were incubated at 37°C for 18 hr with 10 units of enzyme per ml in 10 .ul of the manufacturer's buffer supplemented with 0.2% Triton X-100. With all analyses, control samples subjected to identical conditions in the absence of a modifying agent were included. Reactions were stopped by extracting lipids with watersaturated 1-butanol and derivatives recovered in the 1-butanol and/or water phase were analyzed.
TLC (Fig. 2C) assessed. Lipids were analyzed on TLC developed in Chl/methanol/ water (10:10:3). y/8, Man1/2-GlcN-PI; 8/{, Man2/P-Etn-Man3-GlcN-acyl-PI; A'/O, P-Etn-Man3-GlcN-PI/lyso-PI (7) . *, Dol-PMan; 0 and F, origin and front, respectively. cpm) of each species were analyzed. Treatment with sphingomyelinase (which cleaves phosphorylated head groups from ceramide in sphingomyelin glycolipids) had no effect on any ofthe species. In contrast, as shown in Fig. 3B for H2 and H6 (and as found for each of the other species), incubation with GPI-PLD [which cleaves phosphatidic acid from inositol (see Fig. 1 ) irrespective of inositol acylation] generated butanol phase-retained products with mobilities characteristic of acyl inositol glycans (paralleling that of Tryp {). In accordance with this interpretation, mild alkali treatment [which cleaves acyl linkages (see Fig. 1 )] released 88-96% of the label to the aqueous phase from each of the GPI-PLDtreated species as compared to 76% from the treated r control. In further accordance, incubation of untreated H2-H8 with PI-PLC [which cleaves diradylglycerol from inositol monophosphate (see Fig. 1 ited alkali treatment (20CC for 1 hr) of H2, H6, and H7 were analyzed. As shown in Fig. 3C for Tryp C, H2, and H6, incubation with PI-PLC had no effect on the residual unaltered substrates but differentially cleaved their partially deacylated products. Moreover, GPI-PLD induced comparable release (25% of counts). To exclude heterogeneity of glycans within individual species, the aqueous phasereleased and butanol phase-retained products of alkali treatment of H6 were HN02 deaminated. Analyses of the reduced and dephosphorylated [3H]Man glycan derivatives on P4 columns gave identical elution times.
Next, H2-H7 were subjected to further glycan analyses. Incubation with jack bean a-mannosidase released substantial [3H]Man label from H3, H4, and H6 but none from H5 and only small amounts from H7 ( Table 1) . Dephosphorylation of the glycan fragments deriving from (i) alkali pretreatment and PI-PLC digestion and from (ii) HNO2 deamination and reduction of H7, and sizing of the products on both P4 and AX-S columns gave values coinciding with those of the corresponding glycan fragments of Tryp A' (P2) (Fig. 4) . Similar (Fig. 5B) aligning precisely with H6, H7, and H8 (Fig. 5A) were uniformly observed. Based on these findings, affected PMNs from two patients (J.V. and L.D.) with >95% DAF-and CD59-deficient PMNs were similarly analyzed. As shown in Fig. 5 C and D, the cells from both patients synthesized Dol-P-Man but failed to support assembly of H6-H8. No accumulation of H5 or less polar species was observed, although J.V. showed minor products corresponding in mobilities to H2 and H4. Affected PMNs from two other patients (M.W. and S.T.) next were analyzed for the same or different defects. While studies of three additional controls showed prominent H6-H8 peaks paralleling those of the other normal subjects, studies of both patients showed the complete absence of all three products, with that of M.W. exhibiting minor products with mobilities corresponding to H2 and H4 as seen in J.V. UDP-[3H]GlcNAc labeling demonstrated that as reported for J.V. and P.K. (6) , patients L.D., M.W., and S.T. all synthesized GlcNAc-and GlcN-PI (GPI-A and -B) with normal efficiency (data not shown).
DISCUSSION
The main findings of the present study are tion of intracellular GPI in human cells that properties of acylated inositol phospholip onstration that two ofthe most polar of thes H7, contain core glycans corresponding in s A' (P2) and exhibiting a-mannosidase sensi The cleavage and partitioning of H2-H7 into the aqueous phase following alkali treatment alone suggests that they contain diacylglycerol as do Tryp intermediates (1). However, further studies will be required to allow distinction between exclusively diacyl and mixed diacyl and alkylacyl phospholipids and clarification of the relationship between inositol phospholipids in these mannolipid GPI precursors and those in mature human GPI-anchor structures (13) . Comparative analyses of the HNO2-generated glycan fragments of the aqueous phase-released and butanol phaseretained products indicated that the incomplete alkali release did not reflect heterogeneity of glycans.
The observation of only 30-40%o release of [3H]Man label from H3, H4, and H6 following jack bean a-mannosidase digestion is most likely due to reduced efficiency of enzymatic cleavage of glycolipid as compared to glycan since similar release was measured with Tryp S. Another factor, however, may be that during GPI-anchor core glycan assembly, Man 1 in human GPI precursors is substituted with P-Etn, in accordance with the presence of this substituent in mature human GPI-anchor structures (14, 15) . Such substitution would account for similarities in TLC mobilities between the human and Tryp species despite the presence ofthe third inositol-associated acyl substituent in the former. Observations of shifts in mobilities of the HF and non-HF reduced HNO2 fragments of H5 and H6 on Dionex chromatography (S.H., G.M.P., L.R., and M.E.M., unpublished observations) are consistent with this interpretation.
The greater sensitivity ofH6 than the more polar H7 tojack bean a-mannosidase suggested that a distal Man residue in H7 was substituted. The findings that the (dephosphorylated) glycan derivatives of HNO2 deamination as well as alkali pretreatment and PI-PLC digestion of both H6 and H7 exhibited virtually identical elution behavior on both P-4 and AX-5 columns, which coincided in all cases with the corresponding fragments (Man3-anhydromannitol and Man3-GlcN-inositol) from Tryp A' (P2), argue that human and Tryp intracellular GPIs share common core glycans.
Our previous findings that affected PMNs of two PNH patients assemble GlcNAc-PI and GlcN-PI with efficiency equal to normal cells predicted that the defect in these patients must reside in subsequent steps in GPI-anchor assembly or incorporation into protein. Our observation in the present study, that cells from three other patients similarly synthesize GPI-A and -B but that cells from all of four patients studied lack H6-H8 and at least two show complete absence of earlier intermediates localizes the biochemical block to (i) GlcN-PI acylation or luminal translocation, (ii) P-Etn or Man incorporation, or, conceivably, (iii) altered regulation. Further analyses are necessary to permit delineation of the precise alteration(s) and confirmation of whether the disease is heterogeneous as previously postulated (2, 5) .
